AOMA Summit 2022
Australasia's premier ocular melanoma cross-disciplinary meeting
Day 1 – Friday 29 July 2022 | 9am – 4.30pm
Day 2 – Saturday 30 July | 9am – 12.30pm
Peter MacCallum Cancer Centre
305 Grattan Street, Melbourne VIC 3000
View on Google Maps
Session recordings will be available after the event.
Facilitating collaborations for ocular melanoma
Building on the previously highly successful Australasian Ocular Melanoma Alliance (AOMA) summits, the 3rd AOMA Summit in July 2022 brings together healthcare professionals, researchers and consumers in ocular melanoma to facilitate national and international collaborations for this rare, debilitating and often devastating cancer.
The two-day in-person event includes a scientific program and presentations focused on consumer and advocate involvement.
The AOMA Summit will cover diagnosis and clinical management, clinical trials and registries, laboratory and translational research, current and future treatment options, and consumer and clinician discussion panels.
The AOMA Summit is the premier ocular melanoma cross-disciplinary meeting in Australasia.
- Prof Sarah Coupland, University of Liverpool
- Prof Heinrich Heimann, Liverpool Ocular Oncology Centre
- Prof Mandeep Sagoo, Royal London Hospital
- Dr Amanda Deisher, Mayo Clinic
- Lauren Dalvin M.D., Mayo Clinic
These world experts will enrich the cutting-edge program, joining influential leaders from Australian and New Zealand institutions.
The full program will be available soon.
Download the Summit Flyer.
Australasian Ocular Melanoma Alliance (AOMA)
The Australasian Ocular Melanoma Alliance (AOMA) is the peak national body representing medical, para-medical, nursing and consumer representatives who aim to improve the care and treatment of ocular melanoma patients in Australia and around the world.
AOMA members include Ophthalmologists, Surgeons, Medical and Radiation Oncologists, Pathologists, Allied Health, Scientists, Researchers and Consumer Representatives from across Australia and New Zealand. The focus of this extensive collaboration is treatment paradigms for ocular melanoma, and current and future research.
AOMA was founded in 2017 by Melanoma and Skin Cancer Trials (MASC Trials) and is a MASC Trials priority research special interest group.
Visit the AOMA website for more information.